Full-Time

Medical Operations Lead

Lucis

Lucis

11-50 employees

Subscription-based biomarker analysis for healthspan

No salary listed

London, UK + 2 more

More locations: Barcelona, Spain | Paris, France

In Person

Paris is the primary location; Europe-based candidates must be willing to travel regularly to Paris. Relocation support may be available.

Category
Medical, Clinical & Veterinary

Get referred to Lucis

See people who can refer or advise you

Requirements
  • Be an MD or nurse, or hold an equivalent clinical qualification, with relevant experience.
  • Have real clinical practice experience rather than only academic or desk-based experience.
  • Have run medical operations, clinical quality, clinical programmes, or an equivalent function in a scaled healthtech, diagnostics, pharma, or technology-enabled care company.
  • Have delivered work with operators, including labs and partners, turnaround, and quality.
  • Work effectively with product, engineering, artificial intelligence, operations, and clinical experts.
  • Use artificial intelligence daily.
  • Be fluent in French and English, spoken and written.
Responsibilities
  • Design, document, and improve clinical workflows end-to-end from blood draw and lab intake through results, review, and member follow-up.
  • Own the relationship and operating rhythm with labs and partners, including service-level agreements, turnaround times, incident handling, and quality loops.
  • Maintain clinical standards as labs, markets, and volume expand.
  • Establish clear ownership across medical, product, artificial intelligence, and operations teams.
  • Drive continuous improvement based on operational feedback and member outcomes.
  • Build and run review and escalation processes so complex or sensitive cases move quickly and safely.
  • Establish reliable handoffs between reviewers, Medical Excellence, product, and operations.
  • Own coverage, prioritization, and turnaround for the medical review queue.
  • Own clinical review and sign-off processes on the operations side, including who reviews what, by when, and with what audit trail.
  • Build quality-control systems, documentation standards, and audit trails.
  • Own escalation and medical risk-management processes.
  • Define and monitor clinical performance indicators.
  • Support the operational rollout of new biomarkers, protocols, and artificial intelligence features through training, queues, partner readiness, and go-live quality.
  • Work directly with the product lead, medical team, Medical Excellence, artificial intelligence team, and operations team.
  • Own operational workstreams and deliver fixes with operators.
  • Travel regularly to Paris when based elsewhere in Europe.
Desired Qualifications
  • An additional language is a plus.
  • Relocation support may be available for the primary Paris location.

Lucis runs a European subscription service for preventive health, using regular blood tests to give people personalized insights aimed at extending their healthspan. The product relies on blood draws at 400+ partner labs and analyzes 180+ biomarkers, with AI interpretation reviewed by a medical team, presented through a dynamic dashboard and a prioritized, five-pillar action plan (nutrition, supplements, physical activity, sleep, mental health). It differentiates itself by combining data-driven AI analysis with medical expertise and longitudinal health tracking, rather than providing static reports, all within a European lab and physician network under a subscription model. The goal is to help individuals prevent chronic diseases and take proactive steps to improve long-term health.

Company Size

11-50

Company Stage

Series A

Total Funding

$28.6M

Headquarters

Paris, France

Founded

2023

Get referred to Lucis

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lucis raised $20 million on May 26, 2026, reaching $28 million total funding.
  • More than 10,000 users and one million tests show strong consumer adoption.
  • Seventy-five percent of six-month users improved biomarkers, driving repeat testing and retention.

What critics are saying

  • Lucis still sells self-reported biomarker improvements, not peer-reviewed clinical outcomes.
  • France, Germany, and Italy expansion in 2026 creates regulatory and operational execution risk.
  • If physicians reject AI guidance liability, Lucis becomes a commodity testing reseller.

What makes Lucis unique

  • Lucis combines 110-plus biomarkers, physician review, and AI longitudinal tracking.
  • It partners with Eurofins and Randox across France, Britain, Ireland, and Portugal.
  • The product turns raw blood panels into prioritized actions across nutrition, sleep, and supplements.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

5%

2 year growth

33%
Tech.eu
May 22nd, 2026
Lucis raises $20M Series A to scale AI-driven preventive health platform across Europe

Lucis, a preventive healthcare platform, has raised $20 million in Series A funding led by Singular, with participation from General Catalyst, Y Combinator and angel investors. The round follows an $8 million seed raised four months ago, bringing total funding to $28 million. Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis analyses over 110 blood biomarkers and uses AI-powered insights reviewed by physicians to deliver personalised health guidance. Among users completing six-month follow-ups, 75% improved at least three biomarkers without medication, whilst over 80% opted to retest. The platform has reached 10,000 users across France, the UK, Ireland and Portugal, delivering over one million biomarker tests. Lucis plans to expand into Spain, Germany and Italy by end-2026.

Traders Union
Dec 16th, 2025
Lucis Life secures $8.5M seed round in healthcare and longevity sector

Lucis Life has raised $8.5 million in a seed funding round, led by founder Julien Bouteloup. The healthcare and longevity company achieved this milestone just one year after its launch. The funding round signals growing investor confidence in healthcare innovation. Bouteloup, known for his advocacy around addressing challenges beyond financial returns, has positioned Lucis Life as a leading innovator in the longevity sector. Details about participating investors and specific plans for the capital were not disclosed.

Maddyness
Dec 16th, 2025
Lucis raises funding from Y Combinator and Motier Ventures for predictive health platform

Lucis, a French health-tech startup, is entering the predictive health market with backing from Y Combinator and Motier Ventures. The company addresses a gap in Europe's healthcare system, which excels at treatment but falls short on prevention. Founded by CEO Maxime Berthelot, Lucis focuses on making blood tests more accessible and interpretable for comprehensive health monitoring. The startup identifies blood analysis as the best shortcut for understanding overall health status, but notes that access, cost and particularly interpretation remain significant barriers. Lucis joins a growing field of French longevity-focused startups, including Zoi, founded by former Emmanuel Macron adviser Ismaël Emelien, and Kor, which raised several million euros last year. The trend reflects increasing demand for preventive health solutions amongst tech entrepreneurs and consumers.

Zero
Apr 15th, 2025
You'd be crazy not to take collagen if you care about aging well

- Zero Health launched a Collagen at Zero Nutrition - a clean, 100% vegetarian formula for high absorption.